A statement released earlier today by Bankhaus Lampe KG about EVOTEC (ETR:EVT) bumps the target price to 5.40EUR
- Updated: September 24, 2016
Bankhaus Lampe KG bumped up the target of EVOTEC (ETR:EVT) to 5.40EUR stating a potential upside of 0.13%.
On 9/21/2016, Bankhaus Lampe KG released a statement for EVOTEC (ETR:EVT) bumped up the target price from 0.00EUR to 5.40EUR that suggested an upside of 0.13%.
Displaying a price of 4.77EUR, EVOTEC (ETR:EVT) traded -0.14% lower on the day. The last stock close price is down 0.69% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. EVOTEC has recorded a 50-day moving average of 20.67EUR and a 200-day moving average of 20.14EUR. 102,228 shares of the stock traded hands, down from an average trading volume of 138,891
See Chart Below
EVOTEC has a with a one year low of 16.37EUR and a one year high of 21.25EUR The company’s market cap is currently 0 EUR.
About EVOTEC (ETR:EVT)
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.